Over the past year, and for the first time ever, the US Food and Drug Administration
approved 2 drugs specifically for the treatment of lupus nephritis (LN). As the lupus …

Lupus nephritis is a potentially fatal autoimmune disease for which the current treatment is
ineffective and often toxic. To develop mechanistic hypotheses of disease, we analyzed …

The immune mechanisms that cause tissue injury in lupus nephritis have been challenging
to define. The advent of high-dimensional cellular analyses, such as single-cell RNA …

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by pathologic
T cell–B cell interactions and autoantibody production. Defining the T cell populations that …

Summary Type 1 diabetes (T1D) is a chronic autoimmune disease that involves immune-
mediated destruction of β cells. How β cells respond to immune attack is unknown. We …

Objective Current lupus nephritis (LN) treatments are effective in only 30% of patients,
emphasizing the need for novel therapeutic strategies. We undertook this study to develop …

Targeting immune checkpoint pathways, such as programmed death ligand-1 (PD-L1, also
known as CD274 or B7-H1) or its receptor programmed cell death-1 (PD-1) has shown …

The Accelerating Medicines Partnership (AMP) Lupus Network was established as a
partnership between the National Institutes of Health, pharmaceutical companies, nonprofit …

Lupus nephritis, one of the most serious manifestations of systemic lupus erythematosus
(SLE), has a heterogeneous clinical and pathological presentation. For example …

Introduction Individuals with focal segmental glomerular sclerosis (FSGS) typically undergo
kidney biopsy only once, which limits the ability to characterize kidney cell gene expression …